Trial Profile
A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 21 Aug 2009 Actual patient number (71) added as reported by ClinicalTrials.gov.
- 21 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Mar 2009 New trial record